Rhythm Pharmaceuticals, Inc. (RYTM) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 6.15B USD. 52-week range 74.50 to 122.20 USD. Data as of 2026-10-09.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 ...